Reprioritizing DNA Damage Response: Leveraging Lessons Learned to Develop Next-Generation Inhibitors
Advancements in this field have the potential to transform cancer care and improve quality of life for patients.
Luke Piggott
Advertisement
Principal Scientist at Debiopharm
Articles by Luke Piggott
Advertisement
Latest Updated Articles
Reprioritizing DNA Damage Response: Leveraging Lessons Learned to Develop Next-Generation InhibitorsPublished: December 23rd 2024 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
NIH Implements Contingency Plan as Government Shutdown Impacts Research Funding
2
Focusing on Site Needs and Challenges: Quick Tips for Sponsors/CROs
3
AI in Action: Breaking Down Clinical Trial Bottlenecks
4
AI Everywhere: Architecting the Future of Clinical Trials
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
